PDS Biotechnology(PDSB) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

B.Riley Financial Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Cuts Target Price to $5
Moomoo NewsApr 26 04:31 ET · Ratings
PDS Biotechnology Corporation Announces Three Abstracts Accepted for ASCO 2025 on Versamune HPV Immunotherapy
Quiver QuantitativeApr 23 10:21 ET
Express News | PDS Biotechnology Corp : B. Riley Cuts Target Price to $5 From $7
ReutersApr 21 07:18 ET
Express News | PDS Biotech To Present At American Association of Immunologists' IMMUNOLOGY2025 Annual Meeting May 3-7
BenzingaApr 16 08:05 ET
PDS Biotech Announces PDS01ADC Clinical Data to Be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswireApr 8 08:00 ET
New Analyst Forecast: $PDSB Given 'Buy' Rating
Quiver QuantitativeApr 3 06:27 ET

Comments

Teddy123

Apr 8 20:17

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

$PDS Biotechnology (PDSB.US)$
Groundbreaking Cancer Immunotherapy Data: NCI Reveals PDS01ADC Clinical Results

Trytosaveabit

Mar 27 19:34

Improving

$PDS Biotechnology (PDSB.US)$ Full Year 2024 Financial Results
Net loss for the year ended December 31, 2024, was approximately $37.6 million, or $1.03 per basic and diluted share, compared to a net loss of $42.9 million, or $1.39 per basic and diluted share, for the year ended December 31, 2023. The reduced net loss was primarily the result of decreased operating expenses, partially offset by increased net interest expense.
Research and development expenses for the year ended December 3...

Trytosaveabit

Mar 13 20:01

news

$PDS Biotechnology (PDSB.US)$ Reuters
Just
PDS Biotech Announces FDA Clearance of Ind Application for Combination of Versamune® Muc1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Jaguar8

Mar 13 20:01

NEWS

$PDS Biotechnology (PDSB.US)$
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Thursday, 13th March at 8:00 am
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute
Second Versamune® platform candidate targets MUC1-positive solid tumors
U.S. Patent #12,201,685 covering methods of using combinations of the Versamune® platform and various immun...

1